Although antibodies against the co-inhibitory receptors, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1), exhibit prominent efficacy in several cancer indications, only 20% of cancer patients respond to single-agent checkpoint inhibitors (24). This evidence concerns the gene PDCD1 and cancer.